Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)

Drug (Brand / Generic)

Exondys 51 (eteplirsen)

Product Description

Phosphorodiamidate morpholino oligomer

Current Indication

Duchenne muscular dystrophy

Market Sector

Musculoskeletal disorder

Developer

Sarepta Therapeutics

Development Status

Approved in the US
Expand

Go Top